Last reviewed · How we verify

Sibelium — Competitive Intelligence Brief

Sibelium (FLUNARIZINE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: flunarizine. Area: Pain.

phase 2 flunarizine Adenosine receptor A3, CAAX prenyl protease 2, 5-hydroxytryptamine receptor 1A Pain Small molecule Live · refreshed every 30 min

Target snapshot

Sibelium (FLUNARIZINE). Flunarizine works by binding to the Sigma non-opioid intracellular receptor 1, which is involved in various cellular processes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sibelium TARGET FLUNARIZINE phase 2 flunarizine Adenosine receptor A3, CAAX prenyl protease 2, 5-hydroxytryptamine receptor 1A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (flunarizine class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sibelium — Competitive Intelligence Brief. https://druglandscape.com/ci/flunarizine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing